Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,068,384
  • Shares Outstanding, K 130,388
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -278,160 K
  • EBIT $ -115 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.23
  • Price/Sales 18.61
  • Price/Cash Flow N/A
  • Price/Book 362.43

Options Overview Details

View History
  • Implied Volatility 46.22% ( +4.25%)
  • Historical Volatility 26.10%
  • IV Percentile 81%
  • IV Rank 40.29%
  • IV High 68.01% on 04/08/25
  • IV Low 31.51% on 01/23/25
  • Put/Call Vol Ratio 0.28
  • Today's Volume 111
  • Volume Avg (30-Day) 433
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 13,538
  • Open Int (30-Day) 13,443

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.65
  • Number of Estimates 12
  • High Estimate -0.08
  • Low Estimate -1.34
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
295.82 +6.46%
on 06/12/25
333.70 -5.62%
on 07/03/25
+16.36 (+5.48%)
since 06/11/25
3-Month
225.84 +39.45%
on 04/16/25
333.70 -5.62%
on 07/03/25
+77.17 (+32.46%)
since 04/11/25
52-Week
205.87 +52.98%
on 04/09/25
333.70 -5.62%
on 07/03/25
+53.92 (+20.66%)
since 07/11/24

Most Recent Stories

More News
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

TIL : 24.49 (-8.48%)
ALNY : 314.94 (-2.39%)
3 High-Flying Stocks That Could Soar Even More

SMMT : 25.00 (-3.40%)
ALNY : 314.94 (-2.39%)
AXSM : 108.98 (-1.58%)
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Alnylam Pharmaceuticals ALNY reported first-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate of a loss of 56 cents. The company had incurred a loss of 16 cents...

ALNY : 314.94 (-2.39%)
NVS : 121.02 (-2.19%)
REGN : 567.74 (+1.43%)
RHHBY : 40.4900 (-1.77%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 314.94 (-2.39%)
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

My definition of a high yield is any yield at least twice the level of the S&P 500 's yield. The threshold is currently around 2.56%. An ultra-high yield, in my view, is one that's four times higher than...

BLK : 1,101.64 (-0.22%)
GOOGL : 180.19 (+1.45%)
NVDA : 164.92 (+0.50%)
GOOG : 181.31 (+1.46%)
MMC : 211.74 (-1.38%)
HQL : 13.08 (-2.39%)
SPOT : 709.15 (-0.11%)
BSTZ : 20.54 (-0.29%)
VRTX : 468.85 (-2.23%)
ALNY : 314.94 (-2.39%)
BCAT : 15.20 (-0.13%)
AMGN : 295.27 (-1.70%)
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce...

BAYRY : 7.9800 (-1.72%)
CORT : 71.88 (-0.18%)
ALNY : 314.94 (-2.39%)
SNY : 48.61 (-1.48%)
Incyte Stock: Is INCY Outperforming the Health Care Sector?

Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

XLV : 135.19 (-0.83%)
ALNY : 314.94 (-2.39%)
INCY : 68.59 (-2.49%)
Stocks Recover Early Losses and Close Higher as Magnificent Seven Stocks Rebound

The S&P 500 Index ($SPX ) (SPY ) Friday closed up +0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.39%. June E-mini S&P futures...

GOOGL : 180.19 (+1.45%)
AMAT : 197.93 (-0.05%)
AAPL : 211.16 (-0.59%)
DHI : 136.82 (-2.01%)
$IUXX : 22,780.60 (-0.21%)
ASML : 801.93 (-0.02%)
ZNU25 : 110-230s (-0.45%)
MSFT : 503.32 (+0.37%)
TSLA : 313.51 (+1.17%)
ESU25 : 6,300.00s (-0.38%)
PHM : 114.27 (-0.79%)
NCLH : 22.62 (-2.29%)
Stocks Pare Losses as S&P 500 Looks for Weekly Win

The S&P 500 Index ($SPX ) (SPY ) today is down -0.31%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.18%. June E-mini S&P futures...

AMAT : 197.93 (-0.05%)
TAP : 50.00 (+0.38%)
DHI : 136.82 (-2.01%)
KHC : 27.14 (+2.53%)
TXN : 221.25 (+0.72%)
$IUXX : 22,780.60 (-0.21%)
ASML : 801.93 (-0.02%)
ZNU25 : 110-230s (-0.45%)
HLT : 277.31 (-0.06%)
ESU25 : 6,300.00s (-0.38%)
PHM : 114.27 (-0.79%)
GFS : 41.23 (unch)
Weak Corporate Earnings Results Weigh on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.81%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.95%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.97%. March E-mini S&P futures...

AMAT : 197.93 (-0.05%)
UAL : 87.69 (-4.34%)
TAP : 50.00 (+0.38%)
KHC : 27.14 (+2.53%)
$IUXX : 22,780.60 (-0.21%)
ASML : 801.93 (-0.02%)
ZNU25 : 110-230s (-0.45%)
HLT : 277.31 (-0.06%)
ESU25 : 6,300.00s (-0.38%)
GFS : 41.23 (unch)
QCOM : 157.46 (-1.02%)
NCLH : 22.62 (-2.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 327.88
2nd Resistance Point 324.50
1st Resistance Point 319.72
Last Price 314.94
1st Support Level 311.56
2nd Support Level 308.18
3rd Support Level 303.40

See More

52-Week High 333.70
Last Price 314.94
Fibonacci 61.8% 284.87
Fibonacci 50% 269.79
Fibonacci 38.2% 254.70
52-Week Low 205.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar